Scarica l'app Stockscreener
27.50
15.50%
3.69
Dopo l'orario di chiusura:
28.15
0.65
+2.36%
Instil Bio Inc Borsa (TIL) Ultime notizie
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet - MSN
Instil Bio (TIL) Enhances Axion Bio Board with New Appointment | - GuruFocus
Instil Bio Names John Maraganore, Ph.D., to Board Role - GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., To Board - citybiz
Instil Bio, Inc. Announces the Addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Its Wholly-Owned Subsidiary - MarketScreener
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Yahoo Finance
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer - Dallas Innovates
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news By Investing.com - Investing.com South Africa
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwrig - GuruFocus
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news - Investing.com Canada
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwright & Co. | TIL Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Yahoo Finance
Instil Bio appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Secu - GuruFocus
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Securities | TIL Stock News - GuruFocus
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer - GuruFocus
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer | TIL Stock News - GuruFocus
Instil Bio appoints new Chief Medical Officer - Investing.com
Former Genentech Executive With 15 FDA Approvals Joins Instil Bio to Accelerate Cancer Drug Development - Stock Titan
Instil Bio shares hold as JMP reiterates Market Perform rating By Investing.com - Investing.com India
Instil Bio shares hold as JMP reiterates Market Perform rating - Investing.com Australia
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio Elects Director and Ratifies Auditor - TipRanks
What's Behind The Big Stock Moves? SPRO, TIL, IMAB.... - Nasdaq
Instil Bio Advances Phase 2 Trial in China - TipRanks
(TIL) Proactive Strategies - news.stocktradersdaily.com
Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha
H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com
Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire
Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - GlobeNewswire
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):